Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 6/20 | 0.39 |
| ▸ | CDC42BPB | Q9Y5S2 | 6/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1706372 | 0.88 | ROCK1 (0.36) | ROCK1CDC42BPBROCK2NAMPTEGFR | |
| SCHEMBL1706342 | 0.85 | LRRK2 (0.39) | ROCK1CDC42BPBROCK2LRRK2 | |
| SCHEMBL1707152 | 0.84 | POLB (0.38) | ROCK1CDC42BPBROCK2MEN1KMT2A | |
| SCHEMBL1705916 | 0.84 | POLB (0.38) | ROCK1CDC42BPBROCK2MEN1KMT2A | |
| SCHEMBL1707278 | 0.83 | POLB (0.38) | ROCK1CDC42BPBROCK2MEN1NPC1 | |
| SCHEMBL1951828 | 0.83 | POLB (0.34) | ROCK1CDC42BPBROCK2NAMPTBTK | |
| SCHEMBL1953628 | 0.83 | RAB9A (0.37) | ROCK1CDC42BPBROCK2NAMPTNPC1 | |
| SCHEMBL1951079 | 0.82 | POLB (0.49) | ROCK1CDC42BPBROCK2LRRK2NPC1 | |
| SCHEMBL1953337 | 0.79 | ALDH1A1 (0.40) | ROCK1CDC42BPBROCK2POLB | |
| SCHEMBL1952490 | 0.78 | ITGB3 (0.34) | ROCK1CDC42BPBROCK2NAMPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2440558-B1 | DIHYDROPYRROLONAPHTYRIDINONE COMPOUNDS AS INHIBITORS OF JAK | TAKEDA PHARMACEUTICAL (JP) | 2015-04-01 | — | — | EP | claimed |
| US-8785429-B2 | Dihydropyrrolonaphthyridinone compounds as inhibitors of JAK | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2014-07-22 | — | — | US | claimed |
| US-20130184252-A1 | DIHYDROPYRROLONAPHTHYRIDINONE COMPOUNDS AS INHIBITORS OF JAK | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-18 | — | — | US | claimed |
| US-8420816-B2 | Dihydropyrrolonaphthyridinone compounds as inhibitors of JAK | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-04-16 | — | — | US | claimed |
| US-20110136780-A1 | DIHYDROPYRROLONAPHTYRIDINONE COMPOUNDS AS INHIBITORS OF JAK | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-09 | — | — | US | claimed |
| EP-2440558-B1 | DIHYDROPYRROLONAPHTYRIDINONE COMPOUNDS AS INHIBITORS OF JAK | TAKEDA PHARMACEUTICAL (JP) | 2015-04-01 | — | — | EP | disclosed |
| EP-2440558-B1 | DIHYDROPYRROLONAPHTYRIDINONE COMPOUNDS AS INHIBITORS OF JAK | TAKEDA PHARMACEUTICAL (JP) | 2015-04-01 | — | — | EP | disclosed |
| US-8785429-B2 | Dihydropyrrolonaphthyridinone compounds as inhibitors of JAK | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2014-07-22 | — | — | US | disclosed |
| US-20130184252-A1 | DIHYDROPYRROLONAPHTHYRIDINONE COMPOUNDS AS INHIBITORS OF JAK | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-18 | — | — | US | disclosed |
| US-20130184252-A1 | DIHYDROPYRROLONAPHTHYRIDINONE COMPOUNDS AS INHIBITORS OF JAK | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-18 | — | — | US | disclosed |
| US-8420816-B2 | Dihydropyrrolonaphthyridinone compounds as inhibitors of JAK | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-04-16 | — | — | US | disclosed |
| US-8420816-B2 | Dihydropyrrolonaphthyridinone compounds as inhibitors of JAK | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-04-16 | — | — | US | disclosed |
| US-20110136780-A1 | DIHYDROPYRROLONAPHTYRIDINONE COMPOUNDS AS INHIBITORS OF JAK | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-09 | — | — | US | disclosed |
| US-20110136780-A1 | DIHYDROPYRROLONAPHTYRIDINONE COMPOUNDS AS INHIBITORS OF JAK | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-09 | — | — | US | disclosed |
| WO-2010144486-A1 | DIHYDROPYRROLONAPHTYRIDINONE COMPOUNDS AS INHIBITORS OF JAK | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184252-A1 | DIHYDROPYRROLONAPHTHYRIDINONE COMPOUNDS AS INHIBITORS OF JAK | JAK2, JAK1, JAK3 | ROCK1 261/4885CDC42BPB 2583/4885ROCK2 844/4885 |
| US-20110136780-A1 | DIHYDROPYRROLONAPHTYRIDINONE COMPOUNDS AS INHIBITORS OF JAK | JAK2, JAK1, JAK3 | ROCK1 249/4885CDC42BPB 2631/4885ROCK2 851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.